Weekly Recap | MICOT PHARMA-B -15.72%, MT1013 update fades into sell-offWeekly Review·Nov 14, 2026 at 05:18 AM02335-8.03%
Micot Pharma surges 12% on multiple drug development updatesMarket Movers·Nov 13, 2026 at 02:51 AM02335-8.03%
Micot Pharma climbs 6% as MT1013 Phase III completes follow-upMarket Movers·Nov 10, 2026 at 03:05 AM02335-8.03%
Micot Pharma surges 12% as MT1013 Phase III completes follow-upMarket Movers·Nov 9, 2026 at 05:04 AM02335-8.03%
Shaanxi Micot Says All Participants Complete MT1013 Phase III Trial Treatment and Follow-UpPUBT·Nov 9, 2026 at 04:07 AM02335-8.03%
Weekly Recap | MICOT PHARMA-B +56.62%, MT200605 ethics approval in handWeekly Review·Nov 7, 2026 at 05:47 AM02335-8.03%
Micot Pharma climbs 6% on state grant and clinical approvalMarket Movers·Nov 5, 2026 at 01:31 AM02335-8.03%